Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Patiromer · Veltassa

Other · developed by Vifor Pharma

Approved FDA, Oct 2015
1 Registered trials

What is Patiromer?

Patiromer is a non-absorbed cation exchange polymer with a calcium-sorbitol counterion that binds potassium in the gastrointestinal lumen, increasing fecal potassium excretion and lowering serum potassium. It is studied in hyperkalemia and chronic renal insufficiency.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as
Veltassa
Drug type
Other
Pathways
gastrointestinal potassium excretion
Therapy area
Renal & urology
Developer
Vifor Pharma
In trials of
FMS
FDA status
Approved as Veltassa (October 21, 2015), NDA205739 · FDA label
UNII
1FQ2RY5YHH

✅ FDA-approved uses

From the indications section of the FDA label (version of Jan 31, 2025). Read the full label for the exact wording, limitations and safety information.

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT05136664 Phase 3 Hyperkalemia Completed FMS

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

HyperkalemiaRenal Insufficiency, Chronic

Sources

Updated Nov 8, 2026.

Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.